Lung Cancer Clinical Trial
Official title:
Investigation of the Effectiveness of Tele-pulmonary Rehabilitation After Lung Resection
Verified date | March 2023 |
Source | Dr. Lutfi Kirdar Kartal Training and Research Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
As a result of the review in the literature, no study was found in which tele-pulmonary rehabilitation was applied after physiotherapist-supervised lung resection via video conferencing. Therefore, in this study, it was planned to investigate the effectiveness of tele-pulmonary rehabilitation in patients diagnosed with lung cancer and undergoing lung resection.
Status | Not yet recruiting |
Enrollment | 36 |
Est. completion date | December 1, 2024 |
Est. primary completion date | April 1, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 55 Years to 75 Years |
Eligibility | Inclusion Criteria: - Male and female patients aged 55-75 years diagnosed with lung cancer - Patients who underwent lobectomy, segmentectomy, bilobectomy, and pneumonectomy by either VATS or thoracotomy surgeries - Patients who can use phones and make video calls Exclusion Criteria: - Patients with heart failure or atrial fibrillation - Patients with acute infection at the time of assessment - Patients who have had myocardial infarction in the last six months - Patients with any comorbidities such as uncontrolled diabetes mellitus and/or hypertension - Patients with any problem that would limit physical activity |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Halime Sinem Barutçu |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Functional exercises capacity | A 6-minute walk test will be performed to determine functional exercise capacity. | 8 weeks | |
Primary | Pulmonary function test | Pulmonary function test will be made in accordance with ats criteria | 8 weeks | |
Primary | Peripheral muscle strength | Peripheral muscle strength will be done with 'Lafayette' device | 8 weeks | |
Primary | Upper extremity normal range of motion | Upper extremity normal range of motion will be measured with a manual goniometer | 8 weeks | |
Secondary | Anxiety and depression | Hospital anxiety and depression scale (HAD scale); It will be used to measure and evaluate patients' anxiety and depression scales. | 8 weeks | |
Secondary | Determination of quality of life | EORTC QLQ-C30; This scale is a widely used quality of life scale in cancer patients all over the world. | 8 weeks | |
Secondary | Cognitive functions | Mini mental state test; will be used to evaluate postoperative cognitive dysfunction. | 8 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03918538 -
A Series of Study in Testing Efficacy of Pulmonary Rehabilitation Interventions in Lung Cancer Survivors
|
N/A | |
Recruiting |
NCT05078918 -
Comprehensive Care Program for Their Return to Normal Life Among Lung Cancer Survivors
|
N/A | |
Active, not recruiting |
NCT04548830 -
Safety of Lung Cryobiopsy in People With Cancer
|
Phase 2 | |
Completed |
NCT04633850 -
Implementation of Adjuvants in Intercostal Nerve Blockades for Thoracoscopic Surgery in Pulmonary Cancer Patients
|
||
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT05583916 -
Same Day Discharge for Video-Assisted Thoracoscopic Surgery (VATS) Lung Surgery
|
N/A | |
Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
Not yet recruiting |
NCT06376253 -
A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers
|
Phase 1 | |
Recruiting |
NCT05898594 -
Lung Cancer Screening in High-risk Black Women
|
N/A | |
Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
Active, not recruiting |
NCT03575793 -
A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer
|
Phase 1/Phase 2 | |
Terminated |
NCT01624090 -
Mithramycin for Lung, Esophagus, and Other Chest Cancers
|
Phase 2 | |
Terminated |
NCT03275688 -
NanoSpectrometer Biomarker Discovery and Confirmation Study
|
||
Not yet recruiting |
NCT04931420 -
Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels
|
Phase 2 | |
Recruiting |
NCT06010862 -
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors
|
Phase 1 | |
Recruiting |
NCT06052449 -
Assessing Social Determinants of Health to Increase Cancer Screening
|
N/A | |
Not yet recruiting |
NCT06017271 -
Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer
|
||
Recruiting |
NCT05787522 -
Efficacy and Safety of AI-assisted Radiotherapy Contouring Software for Thoracic Organs at Risk
|